Loading…
Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen
Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although the sphingolipid (SL) ceramide demonstrates known ca...
Saved in:
Published in: | Experimental cell research 2019-08, Vol.381 (2), p.256-264 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3 |
---|---|
cites | cdi_FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3 |
container_end_page | 264 |
container_issue | 2 |
container_start_page | 256 |
container_title | Experimental cell research |
container_volume | 381 |
creator | Morad, Samy A.F. MacDougall, Matthew R. Abdelmageed, Noha Kao, Li-Pin Feith, David J. Tan, Su-Fern Kester, Mark Loughran, Thomas P. Wang, Hong-Gang Cabot, Myles C. |
description | Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although the sphingolipid (SL) ceramide demonstrates known cancer suppressor properties, it’s mechanism of action is multifaceted. Our studies in leukemia and other cancers have demonstrated that when combined with the antiestrogen, tamoxifen, the apoptosis-inducting effect of ceramide is greatly enhanced. The goal of the present study was to establish whether a ceramide-tamoxifen regimen also affects autophagic-driven cellular responses in leukemia. Using the human AML cell line KG-1, we demonstrate that, unlike exposure to the single agents, combination C6-ceramide-tamoxifen upregulated LC3-II expression, inhibited the mTOR signaling pathway, and synergistically induced KG-1 cell death in an Atg5-dependent manner. In addition, colocalization of autophagosome and mitochondria, indicative of mitophagosome formation and mitophagy, was observed. Versatility of the drug regimen was confirmed by experiments in MV4-11 cells, a FLT3-ITD AML mutant. These results indicate that the C6-ceramide-tamoxifen regimen plays a pivotal role inducing autophagy in AML, and thus constitutes a novel therapeutic design.
•Ceramide-tamoxifen regimen affects autophagic-driven responses in human AML cells.•Cell death with the regimen was Atg5-dependent and accompanied by mitophagy.•Inhibition of cell growth was associated with inhibition of mTOR signaling. |
doi_str_mv | 10.1016/j.yexcr.2019.05.021 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6909922</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014482719302629</els_id><sourcerecordid>2232100866</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3</originalsourceid><addsrcrecordid>eNp9kc1uFDEQhC0EIkvgCZCQj1xmsHv-DyChCEikSHCAs-W12xMvY3uxPavs2-NkQwQXTn2or6tbVYS85qzmjPfvdvURb1WsgfGpZl3NgD8hG84mVkEL8JRsGONt1Y4wnJEXKe0YY-PI--fkrOGcw9D0G5K-2UPIcqExLEiDoc7msL-R85FaTyOmffDpXpBqzUjdEZcwow9roguuP9FZSXOgkiqM0lmNVZYu3FqDvlLBZ2m99TPVcZ2L3Wwd-pfkmZFLwlcP85z8-Pzp-8Vldf31y9XFx-tKddDlqjGD1qAYk7gdW6m3YLZGQ4tK65Y12BkDwyjHoSg9GI5Gc8Bp7DrTdNCb5px8OPnu161DrdDnKBexj9bJeBRBWvGv4u2NmMNB9BObJoBi8PbBIIZfK6YsnE0Kl0V6LAGIggAvofZ9QZsTqmJIKaJ5PMOZuKtL7MR9XeKuLsE6UeoqW2_-_vBx508_BXh_ArDkdLAYRVIWvUJtI6osdLD_PfAby02sZg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2232100866</pqid></control><display><type>article</type><title>Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen</title><source>Elsevier</source><creator>Morad, Samy A.F. ; MacDougall, Matthew R. ; Abdelmageed, Noha ; Kao, Li-Pin ; Feith, David J. ; Tan, Su-Fern ; Kester, Mark ; Loughran, Thomas P. ; Wang, Hong-Gang ; Cabot, Myles C.</creator><creatorcontrib>Morad, Samy A.F. ; MacDougall, Matthew R. ; Abdelmageed, Noha ; Kao, Li-Pin ; Feith, David J. ; Tan, Su-Fern ; Kester, Mark ; Loughran, Thomas P. ; Wang, Hong-Gang ; Cabot, Myles C.</creatorcontrib><description>Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although the sphingolipid (SL) ceramide demonstrates known cancer suppressor properties, it’s mechanism of action is multifaceted. Our studies in leukemia and other cancers have demonstrated that when combined with the antiestrogen, tamoxifen, the apoptosis-inducting effect of ceramide is greatly enhanced. The goal of the present study was to establish whether a ceramide-tamoxifen regimen also affects autophagic-driven cellular responses in leukemia. Using the human AML cell line KG-1, we demonstrate that, unlike exposure to the single agents, combination C6-ceramide-tamoxifen upregulated LC3-II expression, inhibited the mTOR signaling pathway, and synergistically induced KG-1 cell death in an Atg5-dependent manner. In addition, colocalization of autophagosome and mitochondria, indicative of mitophagosome formation and mitophagy, was observed. Versatility of the drug regimen was confirmed by experiments in MV4-11 cells, a FLT3-ITD AML mutant. These results indicate that the C6-ceramide-tamoxifen regimen plays a pivotal role inducing autophagy in AML, and thus constitutes a novel therapeutic design.
•Ceramide-tamoxifen regimen affects autophagic-driven responses in human AML cells.•Cell death with the regimen was Atg5-dependent and accompanied by mitophagy.•Inhibition of cell growth was associated with inhibition of mTOR signaling.</description><identifier>ISSN: 0014-4827</identifier><identifier>EISSN: 1090-2422</identifier><identifier>DOI: 10.1016/j.yexcr.2019.05.021</identifier><identifier>PMID: 31112736</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Autophagy ; Ceramide ; Leukemia ; Mitophagy ; Sphingolipids ; Tamoxifen</subject><ispartof>Experimental cell research, 2019-08, Vol.381 (2), p.256-264</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3</citedby><cites>FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31112736$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morad, Samy A.F.</creatorcontrib><creatorcontrib>MacDougall, Matthew R.</creatorcontrib><creatorcontrib>Abdelmageed, Noha</creatorcontrib><creatorcontrib>Kao, Li-Pin</creatorcontrib><creatorcontrib>Feith, David J.</creatorcontrib><creatorcontrib>Tan, Su-Fern</creatorcontrib><creatorcontrib>Kester, Mark</creatorcontrib><creatorcontrib>Loughran, Thomas P.</creatorcontrib><creatorcontrib>Wang, Hong-Gang</creatorcontrib><creatorcontrib>Cabot, Myles C.</creatorcontrib><title>Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen</title><title>Experimental cell research</title><addtitle>Exp Cell Res</addtitle><description>Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although the sphingolipid (SL) ceramide demonstrates known cancer suppressor properties, it’s mechanism of action is multifaceted. Our studies in leukemia and other cancers have demonstrated that when combined with the antiestrogen, tamoxifen, the apoptosis-inducting effect of ceramide is greatly enhanced. The goal of the present study was to establish whether a ceramide-tamoxifen regimen also affects autophagic-driven cellular responses in leukemia. Using the human AML cell line KG-1, we demonstrate that, unlike exposure to the single agents, combination C6-ceramide-tamoxifen upregulated LC3-II expression, inhibited the mTOR signaling pathway, and synergistically induced KG-1 cell death in an Atg5-dependent manner. In addition, colocalization of autophagosome and mitochondria, indicative of mitophagosome formation and mitophagy, was observed. Versatility of the drug regimen was confirmed by experiments in MV4-11 cells, a FLT3-ITD AML mutant. These results indicate that the C6-ceramide-tamoxifen regimen plays a pivotal role inducing autophagy in AML, and thus constitutes a novel therapeutic design.
•Ceramide-tamoxifen regimen affects autophagic-driven responses in human AML cells.•Cell death with the regimen was Atg5-dependent and accompanied by mitophagy.•Inhibition of cell growth was associated with inhibition of mTOR signaling.</description><subject>Autophagy</subject><subject>Ceramide</subject><subject>Leukemia</subject><subject>Mitophagy</subject><subject>Sphingolipids</subject><subject>Tamoxifen</subject><issn>0014-4827</issn><issn>1090-2422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kc1uFDEQhC0EIkvgCZCQj1xmsHv-DyChCEikSHCAs-W12xMvY3uxPavs2-NkQwQXTn2or6tbVYS85qzmjPfvdvURb1WsgfGpZl3NgD8hG84mVkEL8JRsGONt1Y4wnJEXKe0YY-PI--fkrOGcw9D0G5K-2UPIcqExLEiDoc7msL-R85FaTyOmffDpXpBqzUjdEZcwow9roguuP9FZSXOgkiqM0lmNVZYu3FqDvlLBZ2m99TPVcZ2L3Wwd-pfkmZFLwlcP85z8-Pzp-8Vldf31y9XFx-tKddDlqjGD1qAYk7gdW6m3YLZGQ4tK65Y12BkDwyjHoSg9GI5Gc8Bp7DrTdNCb5px8OPnu161DrdDnKBexj9bJeBRBWvGv4u2NmMNB9BObJoBi8PbBIIZfK6YsnE0Kl0V6LAGIggAvofZ9QZsTqmJIKaJ5PMOZuKtL7MR9XeKuLsE6UeoqW2_-_vBx508_BXh_ArDkdLAYRVIWvUJtI6osdLD_PfAby02sZg</recordid><startdate>20190815</startdate><enddate>20190815</enddate><creator>Morad, Samy A.F.</creator><creator>MacDougall, Matthew R.</creator><creator>Abdelmageed, Noha</creator><creator>Kao, Li-Pin</creator><creator>Feith, David J.</creator><creator>Tan, Su-Fern</creator><creator>Kester, Mark</creator><creator>Loughran, Thomas P.</creator><creator>Wang, Hong-Gang</creator><creator>Cabot, Myles C.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190815</creationdate><title>Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen</title><author>Morad, Samy A.F. ; MacDougall, Matthew R. ; Abdelmageed, Noha ; Kao, Li-Pin ; Feith, David J. ; Tan, Su-Fern ; Kester, Mark ; Loughran, Thomas P. ; Wang, Hong-Gang ; Cabot, Myles C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Autophagy</topic><topic>Ceramide</topic><topic>Leukemia</topic><topic>Mitophagy</topic><topic>Sphingolipids</topic><topic>Tamoxifen</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morad, Samy A.F.</creatorcontrib><creatorcontrib>MacDougall, Matthew R.</creatorcontrib><creatorcontrib>Abdelmageed, Noha</creatorcontrib><creatorcontrib>Kao, Li-Pin</creatorcontrib><creatorcontrib>Feith, David J.</creatorcontrib><creatorcontrib>Tan, Su-Fern</creatorcontrib><creatorcontrib>Kester, Mark</creatorcontrib><creatorcontrib>Loughran, Thomas P.</creatorcontrib><creatorcontrib>Wang, Hong-Gang</creatorcontrib><creatorcontrib>Cabot, Myles C.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morad, Samy A.F.</au><au>MacDougall, Matthew R.</au><au>Abdelmageed, Noha</au><au>Kao, Li-Pin</au><au>Feith, David J.</au><au>Tan, Su-Fern</au><au>Kester, Mark</au><au>Loughran, Thomas P.</au><au>Wang, Hong-Gang</au><au>Cabot, Myles C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen</atitle><jtitle>Experimental cell research</jtitle><addtitle>Exp Cell Res</addtitle><date>2019-08-15</date><risdate>2019</risdate><volume>381</volume><issue>2</issue><spage>256</spage><epage>264</epage><pages>256-264</pages><issn>0014-4827</issn><eissn>1090-2422</eissn><abstract>Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although the sphingolipid (SL) ceramide demonstrates known cancer suppressor properties, it’s mechanism of action is multifaceted. Our studies in leukemia and other cancers have demonstrated that when combined with the antiestrogen, tamoxifen, the apoptosis-inducting effect of ceramide is greatly enhanced. The goal of the present study was to establish whether a ceramide-tamoxifen regimen also affects autophagic-driven cellular responses in leukemia. Using the human AML cell line KG-1, we demonstrate that, unlike exposure to the single agents, combination C6-ceramide-tamoxifen upregulated LC3-II expression, inhibited the mTOR signaling pathway, and synergistically induced KG-1 cell death in an Atg5-dependent manner. In addition, colocalization of autophagosome and mitochondria, indicative of mitophagosome formation and mitophagy, was observed. Versatility of the drug regimen was confirmed by experiments in MV4-11 cells, a FLT3-ITD AML mutant. These results indicate that the C6-ceramide-tamoxifen regimen plays a pivotal role inducing autophagy in AML, and thus constitutes a novel therapeutic design.
•Ceramide-tamoxifen regimen affects autophagic-driven responses in human AML cells.•Cell death with the regimen was Atg5-dependent and accompanied by mitophagy.•Inhibition of cell growth was associated with inhibition of mTOR signaling.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31112736</pmid><doi>10.1016/j.yexcr.2019.05.021</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-4827 |
ispartof | Experimental cell research, 2019-08, Vol.381 (2), p.256-264 |
issn | 0014-4827 1090-2422 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6909922 |
source | Elsevier |
subjects | Autophagy Ceramide Leukemia Mitophagy Sphingolipids Tamoxifen |
title | Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T23%3A56%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pivotal%20role%20of%20mitophagy%20in%20response%20of%20acute%20myelogenous%20leukemia%20to%20a%20ceramide-tamoxifen-containing%20drug%20regimen&rft.jtitle=Experimental%20cell%20research&rft.au=Morad,%20Samy%20A.F.&rft.date=2019-08-15&rft.volume=381&rft.issue=2&rft.spage=256&rft.epage=264&rft.pages=256-264&rft.issn=0014-4827&rft.eissn=1090-2422&rft_id=info:doi/10.1016/j.yexcr.2019.05.021&rft_dat=%3Cproquest_pubme%3E2232100866%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2232100866&rft_id=info:pmid/31112736&rfr_iscdi=true |